United Therapeutics Corporation (UTHR) EV/EBITDA Ratio: 14.41x
Is United Therapeutics Corporation’s EV/EBITDA ratio high or low?
United Therapeutics Corporation's EV/EBITDA ratio of 14.41x is 27% above its 5-year average of 11.38x, near the high end of its 5-year range (7.03x–17.42x).
As of Saturday, June 13, 2026. 21.20% above its 12-month average of 11.89x.
UTHR EV/EBITDA Ratio Chart
UTHR Average EV/EBITDA Ratio Chart
UTHR Current vs Average EV/EBITDA Ratio Chart
UTHR EV/EBITDA Ratio Metrics
EV/EBITDA RATIO
14.41x
EV/EBITDA RATIO AVG TTM
11.89x
EV/EBITDA RATIO AVG 3Y
10.20x
EV/EBITDA RATIO AVG 5Y
11.38x
EV/EBITDA RATIO AVG 10Y
9.11x
EV/EBITDA RATIO AVG 15Y
9.91x
EV/EBITDA RATIO AVG 20Y
23.02x
CURRENT VS TTM AVG
+21.20%
CURRENT VS 3Y AVG
+41.21%
CURRENT VS 5Y AVG
+26.59%
CURRENT VS 10Y AVG
+58.10%
CURRENT VS 15Y AVG
+45.46%
CURRENT VS 20Y AVG
-37.40%
UTHR Competitors' EV/EBITDA Ratio
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| United Therapeutics Corporation (UTHR) | $23.17B | 14.41x | 11.89x | 10.20x | 11.38x |
| Waters Corporation (WAT) | $23.17B | 37.11x | 21.72x | 21.28x | 21.47x |
| BioNTech SE (BNTX) | $22.90B | N/A | 51.40x | 19.63x | 20.05x |
| Mettler-Toledo International Inc. (MTD) | $22.86B | 20.60x | 23.58x | 23.88x | 26.49x |
| Labcorp Holdings Inc. (LH) | $21.83B | 13.73x | 14.69x | 14.58x | 11.71x |
| Veeva Systems Inc. (VEEV) | $25.92B | 19.17x | 33.23x | 43.96x | 53.99x |
| Moderna, Inc. (MRNA) | $19.80B | N/A | 12.39x | 25.28x | 25.28x |
| DexCom, Inc. (DXCM) | $29.08B | 20.28x | 25.32x | 42.50x | 70.63x |
| Hologic, Inc. (HOLX) | $16.97B | 17.28x | 15.01x | 15.35x | 12.41x |
| Biogen Inc. (BIIB) | $29.53B | 12.16x | 8.71x | 11.20x | 12.24x |
EV/EBITDA vs. its own history
At 14.4, EV/EBITDA is richer than usual, sitting higher than 65% of its 20-year history.
20-year low
3.4
median
10.8
20-year high
327.9
United Therapeutics Corporation EV/EBITDA Ratio Formula & Definition
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
United Therapeutics Corporation EV/EBITDA Ratio FAQ
- What is the EV/EBITDA ratio for United Therapeutics Corporation (UTHR)?
- The EV/EBITDA ratio for UTHR stock is 14.41x.
- Is United Therapeutics Corporation's EV/EBITDA ratio high or low?
- United Therapeutics Corporation's EV/EBITDA ratio of 14.41x is 27% above its 5-year average of 11.38x, near the high end of its 5-year range (7.03x–17.42x).
- What is the TTM average EV/EBITDA ratio for United Therapeutics Corporation (UTHR)?
- The TTM average EV/EBITDA ratio for UTHR stock is 11.89x.
- What is the 3Y average EV/EBITDA ratio for United Therapeutics Corporation (UTHR)?
- The 3Y average EV/EBITDA ratio for UTHR stock is 10.20x.
- What is the 5Y average EV/EBITDA ratio for United Therapeutics Corporation (UTHR)?
- The 5Y average EV/EBITDA ratio for UTHR stock is 11.38x.
- What is the 10Y average EV/EBITDA ratio for United Therapeutics Corporation (UTHR)?
- The 10Y average EV/EBITDA ratio for UTHR stock is 9.11x.
- What is the 15Y average EV/EBITDA ratio for United Therapeutics Corporation (UTHR)?
- The 15Y average EV/EBITDA ratio for UTHR stock is 9.91x.
- What is the 20Y average EV/EBITDA ratio for United Therapeutics Corporation (UTHR)?
- The 20Y average EV/EBITDA ratio for UTHR stock is 23.02x.
United Therapeutics Corporation EV/EBITDA Ratio History
| DATE | EV/EBITDA RATIO |
|---|---|
| 2026-06-12 | 14.41x |
| 2026-06-11 | 14.40x |
| 2026-06-10 | 14.36x |
| 2026-06-09 | 14.61x |
| 2026-06-08 | 14.38x |
| 2026-06-05 | 14.52x |
| 2026-06-04 | 14.46x |
| 2026-06-03 | 14.51x |
| 2026-06-02 | 14.25x |
| 2026-06-01 | 14.38x |
| 2026-05-29 | 14.71x |
| 2026-05-28 | 14.86x |
| 2026-05-27 | 15.09x |
| 2026-05-26 | 15.31x |
| 2026-05-22 | 15.03x |
| 2026-05-21 | 14.96x |
| 2026-05-20 | 14.91x |
| 2026-05-19 | 14.99x |
| 2026-05-18 | 14.99x |
| 2026-05-15 | 15.04x |
| 2026-05-14 | 15.23x |
| 2026-05-13 | 15.34x |
| 2026-05-12 | 15.40x |
| 2026-05-11 | 15.07x |
| 2026-05-08 | 14.93x |
| 2026-05-07 | 15.05x |
| 2026-05-06 | 15.81x |
| 2026-05-05 | 14.75x |
| 2026-05-04 | 15.00x |
| 2026-05-01 | 14.70x |
| 2026-04-30 | 14.73x |
| 2026-04-29 | 14.72x |
| 2026-04-28 | 14.67x |
| 2026-04-27 | 14.61x |
| 2026-04-24 | 14.61x |
| 2026-04-23 | 14.77x |
| 2026-04-22 | 14.81x |
| 2026-04-21 | 14.79x |
| 2026-04-20 | 14.79x |
| 2026-04-17 | 15.19x |
| 2026-04-16 | 14.98x |
| 2026-04-15 | 14.90x |
| 2026-04-14 | 14.93x |
| 2026-04-13 | 14.90x |
| 2026-04-10 | 14.74x |
| 2026-04-09 | 14.82x |
| 2026-04-08 | 15.01x |
| 2026-04-07 | 14.57x |
| 2026-04-06 | 14.41x |
| 2026-04-02 | 14.55x |
| 2026-04-01 | 14.70x |
| 2026-03-31 | 15.32x |
| 2026-03-30 | 15.19x |
| 2026-03-27 | 13.40x |
| 2026-03-26 | 13.67x |
| 2026-03-25 | 13.92x |
| 2026-03-24 | 13.65x |
| 2026-03-23 | 13.36x |
| 2026-03-20 | 13.44x |
| 2026-03-19 | 13.52x |
| 2026-03-18 | 13.61x |
| 2026-03-17 | 13.87x |
| 2026-03-16 | 13.72x |
| 2026-03-13 | 13.77x |
| 2026-03-12 | 13.68x |
| 2026-03-11 | 14.00x |
| 2026-03-10 | 13.76x |
| 2026-03-09 | 13.58x |
| 2026-03-06 | 12.18x |
| 2026-03-05 | 12.37x |
| 2026-03-04 | 12.51x |
| 2026-03-03 | 12.74x |
| 2026-03-02 | 13.16x |
| 2026-02-27 | 12.89x |
| 2026-02-26 | 12.88x |
| 2026-02-25 | 13.74x |
| 2026-02-24 | 12.46x |
| 2026-02-23 | 12.49x |
| 2026-02-20 | 12.46x |
| 2026-02-19 | 12.65x |
| 2026-02-18 | 12.53x |
| 2026-02-17 | 12.70x |
| 2026-02-13 | 12.46x |
| 2026-02-12 | 12.53x |
| 2026-02-11 | 12.52x |
| 2026-02-10 | 12.45x |
| 2026-02-09 | 12.45x |
| 2026-02-06 | 12.79x |
| 2026-02-05 | 12.61x |
| 2026-02-04 | 12.71x |
| 2026-02-03 | 12.59x |
| 2026-02-02 | 12.50x |
| 2026-01-30 | 12.35x |
| 2026-01-29 | 12.30x |
| 2026-01-28 | 12.29x |
| 2026-01-27 | 12.55x |
| 2026-01-26 | 12.45x |
| 2026-01-23 | 12.33x |
| 2026-01-22 | 12.42x |
| 2026-01-21 | 12.35x |
| 2026-01-20 | 12.31x |
| 2026-01-16 | 12.22x |
| 2026-01-15 | 12.42x |
| 2026-01-14 | 12.52x |
| 2026-01-13 | 12.55x |
| 2026-01-12 | 12.70x |
| 2026-01-09 | 12.73x |
| 2026-01-08 | 12.94x |
| 2026-01-07 | 13.29x |
| 2026-01-06 | 13.27x |
| 2026-01-05 | 12.91x |
| 2026-01-02 | 13.10x |
| 2025-12-31 | 12.84x |
| 2025-12-30 | 13.09x |
| 2025-12-29 | 13.27x |
| 2025-12-26 | 13.39x |
| 2025-12-24 | 13.60x |
| 2025-12-23 | 13.48x |
| 2025-12-22 | 13.57x |
| 2025-12-19 | 13.67x |
| 2025-12-18 | 13.39x |
| 2025-12-17 | 13.50x |
| 2025-12-16 | 13.19x |
| 2025-12-15 | 13.20x |
| 2025-12-12 | 13.03x |
| 2025-12-11 | 12.87x |
| 2025-12-10 | 12.77x |
| 2025-12-09 | 12.54x |
| 2025-12-08 | 12.62x |
| 2025-12-05 | 12.90x |
| 2025-12-04 | 12.75x |
| 2025-12-03 | 12.66x |
| 2025-12-02 | 12.48x |
| 2025-12-01 | 12.64x |
| 2025-11-28 | 12.80x |
| 2025-11-26 | 12.87x |
| 2025-11-25 | 12.80x |
| 2025-11-24 | 12.56x |
| 2025-11-21 | 12.49x |
| 2025-11-20 | 12.49x |
| 2025-11-19 | 12.54x |
| 2025-11-18 | 12.54x |
| 2025-11-17 | 12.41x |
| 2025-11-14 | 12.26x |
| 2025-11-13 | 12.15x |
| 2025-11-12 | 12.13x |
| 2025-11-11 | 12.06x |
| 2025-11-10 | 11.92x |
| 2025-11-07 | 11.78x |
| 2025-11-06 | 11.92x |
| 2025-11-05 | 11.74x |
| 2025-11-04 | 11.46x |
| 2025-11-03 | 11.49x |
| 2025-10-31 | 11.68x |
| 2025-10-30 | 11.90x |
| 2025-10-29 | 11.95x |
| 2025-10-28 | 11.12x |
| 2025-10-27 | 11.28x |
| 2025-10-24 | 11.21x |
| 2025-10-23 | 11.43x |
| 2025-10-22 | 11.30x |
| 2025-10-21 | 11.32x |
| 2025-10-20 | 11.62x |
| 2025-10-17 | 11.64x |
| 2025-10-16 | 11.62x |
| 2025-10-15 | 11.60x |
| 2025-10-14 | 11.65x |
| 2025-10-13 | 11.83x |
| 2025-10-10 | 11.83x |
| 2025-10-09 | 11.99x |
| 2025-10-08 | 12.09x |
| 2025-10-07 | 12.32x |
| 2025-10-06 | 12.22x |
| 2025-10-03 | 12.21x |
| 2025-10-02 | 11.93x |
| 2025-10-01 | 11.78x |
| 2025-09-30 | 11.23x |
| 2025-09-29 | 11.38x |
| 2025-09-26 | 11.62x |
| 2025-09-25 | 11.41x |
| 2025-09-24 | 11.80x |
| 2025-09-23 | 11.66x |
| 2025-09-22 | 11.10x |
| 2025-09-19 | 11.18x |
| 2025-09-18 | 10.96x |
| 2025-09-17 | 10.78x |
| 2025-09-16 | 10.61x |
| 2025-09-15 | 10.76x |
| 2025-09-12 | 10.82x |
| 2025-09-11 | 10.81x |
| 2025-09-10 | 10.57x |
| 2025-09-09 | 10.78x |
| 2025-09-08 | 10.51x |
| 2025-09-05 | 10.68x |
| 2025-09-04 | 10.10x |
| 2025-09-03 | 10.42x |
| 2025-09-02 | 10.81x |
| 2025-08-29 | 7.90x |
| 2025-08-28 | 7.97x |
| 2025-08-27 | 7.92x |
| 2025-08-26 | 8.03x |
| 2025-08-25 | 7.92x |
| 2025-08-22 | 8.12x |
| 2025-08-21 | 8.07x |
| 2025-08-20 | 7.95x |
| 2025-08-19 | 8.15x |
| 2025-08-18 | 8.17x |
| 2025-08-15 | 8.14x |
| 2025-08-14 | 8.11x |
| 2025-08-13 | 8.04x |
| 2025-08-12 | 7.80x |
| 2025-08-11 | 7.77x |
| 2025-08-08 | 7.81x |
| 2025-08-07 | 7.75x |
| 2025-08-06 | 7.83x |
| 2025-08-05 | 7.90x |
| 2025-08-04 | 7.55x |
| 2025-08-01 | 7.60x |
| 2025-07-31 | 7.03x |
| 2025-07-30 | 7.24x |
| 2025-07-29 | 7.92x |
| 2025-07-28 | 7.94x |
| 2025-07-25 | 8.13x |
| 2025-07-24 | 8.19x |
| 2025-07-23 | 8.17x |
| 2025-07-22 | 7.93x |
| 2025-07-21 | 7.79x |
| 2025-07-18 | 7.76x |
| 2025-07-17 | 7.92x |
| 2025-07-16 | 7.94x |
| 2025-07-15 | 7.79x |
| 2025-07-14 | 7.93x |
| 2025-07-11 | 7.86x |
| 2025-07-10 | 8.00x |
| 2025-07-09 | 8.02x |
| 2025-07-08 | 7.83x |
| 2025-07-07 | 7.71x |
| 2025-07-03 | 7.83x |
| 2025-07-02 | 7.85x |
| 2025-07-01 | 7.72x |
| 2025-06-30 | 7.62x |
| 2025-06-27 | 7.52x |
| 2025-06-26 | 7.52x |
| 2025-06-25 | 7.58x |
| 2025-06-24 | 7.69x |
| 2025-06-23 | 7.59x |
| 2025-06-20 | 7.72x |
| 2025-06-18 | 7.75x |
| 2025-06-17 | 7.60x |
| 2025-06-16 | 7.65x |
| 2025-06-13 | 7.50x |
| 2025-06-12 | 7.58x |
| 2025-06-11 | 7.29x |
| 2025-06-10 | 7.44x |
| 2025-06-09 | 8.86x |
| 2025-06-06 | 8.78x |
| 2025-06-05 | 8.59x |
| 2025-06-04 | 8.72x |
| 2025-06-03 | 8.73x |
| 2025-06-02 | 8.77x |
Showing the most recent 260 of 4,530 data points. The chart above shows the full history.
Related Metrics
About United Therapeutics Corporation
United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in patients with PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD). Orenitram, a treprostinil tablet formulation, also aims to boost the exercise capabilities of PAH patients. Unituxin, a monoclonal antibody utilized in the treatment of high-risk neuroblastoma. Adcirca, an oral PDE-5 inhibitor, which helps improve exercise performance in those with PAH. United Therapeutics also maintains a robust development pipeline, including: Tyvaso DPI, a dry powder inhaler version of Tyvaso. The Remunity Pump, a compact, lightweight, and durable infusion system for treprostinil, accompanied by a separate controller. RemoPro and Ralinepag, both investigational treatments for PAH. Aurora-GT, a gene therapy product focused on regenerating blood vessels within the lungs. Clinical trials such as Tyvaso PERFECT and TETON, which are evaluating Tyvaso's efficacy in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The company has forged strategic alliances and licensing agreements with various entities, such as DEKA Research & Development Corp. for a semi-disposable subcutaneous treprostinil delivery system; MannKind Corporation for the development and licensing of treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. for the development of Ralinepag. Established in 1996, United Therapeutics Corporation is headquartered in Silver Spring, Maryland.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Martine A. Rothblatt